In Situ Hybridization Market by Products (Consumables, Instruments, Software), Technology (DNA FISH, RNA FISH, PNA FISH, CISH), Application (Cancer, Immunology, Neuroscience, Cytology), End User (Hospitals, Pharma, Biotech, CROs) & Region - Global Forecasts to 2027
The global In situ hybridization market in terms of revenue was estimated to be worth $1.5 billion in 2022 and is poised to reach $2.8 billion by 2027, growing at a CAGR of 12.6% from 2022 to 2027. An increase in the adoption of situ hybridization (ISH) products in managing genetic disorders and cancer patients is set to drive market growth. Emerging economies offer significant opportunities for key market players looking to strengthen their presence. In developed countries, high-quality molecular diagnostic tests are readily available. As a result, emerging markets such as India, China, and Brazil, offer significant growth opportunities for MDx-based technology (including ISH) owing to the rising geriatric population, the growing prevalence of infectious diseases, and various types of cancers.
To know about the assumptions considered for the study, Request for Free Sample Report
In Situ Hybridization Market Dynamics
Drivers: Rising incidence of genetic disorders and cancer
Over the years, there has been an increase in the incidence of cancer worldwide. Over the last two decades, extensive studies related to human diseases have recognized recurrent genomic abnormalities as potential driving factors for various cancers. Cytogenetic assays such as ISH help integrate IHC and DNA FISH to complete the in situ tool-set for researchers to discover, develop, and implement new-generation diagnostic procedures. Directly imaging gene expression in situ at the RNA level delivers a unique insight into the interplay between cancer cells and the tumor microenvironment while cancer progresses. A similar pattern is also followed for genetic disorders.
Challenges: Shortage of skilled professionals
To conduct an ISH-based test, it is crucial to understand the molecular information of a chromosome or a gene. In addition, the reluctance to move from manual operations to automation is another challenge for market growth. Many providers find it challenging to transition to IT-based approaches from manual or traditional methods or may not prefer to make the shift at all. Thus, the shortage of skilled, well-trained, and technically knowledgeable laboratory technicians to conduct ISH-based diagnosis limits their overall adoption, particularly in emerging markets.
The consumables accounted for the largest share of the in situ hybridization market in 2021.
The global market is segmented into consumables, instruments, and software based on product. In 2021, the ISH consumables segment accounted for the largest share of this market. Robust funding by private and government authorities in cancer research is set to boost the adoption of ISH products. In addition, advent of novel technologies employed in tissue diagnostic protocols and IVD applications is expected to further drive the segment growth through the forecast period..
The DNA FISH technology segment dominated the fluorescent in situ hybridization market in 2021.
Based on the technology, the market is FISH (fluorescent in situ hybridization) and CISH (chromogenic in situ hybridization). The FISH segment is further categorized into DNA FISH, RNA FISH, and PNA FISH. In 2021, the DNA FISH segment dominated the fluorescent in-situ hybridization market with the highest revenue share. DNA FISH utilizes DNA as a probe to detect the nucleic acid sequence during FISH. DNA FISH is often used in cytogenetics and cancer diagnostics and can detect aberrations in genomes, which result in genetic abnormalities. The FISH procedure's success depends on the genetic material's stability (DNA/RNA). Hence, DNA is preferred over RNA due to the stability acquired from the hydrogen bonds of its double helix structure.
In 2021, the academic and research institutes have generated the second highest revenue in the in situ hybridization market.
Based on the end user, the global in situ hybridization market is segmented into hospital & diagnostic laboratories, academic and research institutes, CROs, and pharmaceutical & biotechnology companies. In 2021, the academic and research institutes generated the second highest revenue in the global market. Academic research laboratories use ISH products for educational purposes, such as understanding the complex processes involved in disease formation. ISH is often used to study different diseases, such as cancer, in which chromosomal abnormalities occur where extra copies of chromosomes are present or a portion of a chromosome is deleted, repeated, or reversed in orientation. Increasing collaborations between pharma, diagnostic companies, and research institutes are expected to drive market growth for this segment.
North America was the largest regional market for in situ hybridization in 2021.
Geographically, the In Situ Hybridization Market is segmented into North America, Europe, Asia Pacific, RoW (Rest of the World). The North American region dominated this market in 2021 and this dominance is anticipated to continue throughout the forecast period. The US has emerged as the key revenue contributor to this region, with robust public-private funding to develop novel companion diagnostics.
To know about the assumptions considered for the study, download the pdf brochure
Some of the key players include Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (US) Danaher Corporation (US), Thermofisher Scientific (US), Abnova Corporation (Taiwan), BioGenex Laboratories (US), Bio-Techne Corporation (US), Biocare Medical, and Bio SB (US)
In situ Hybridization Market Report Scope
|
Report Metric |
Details |
|
Market Revenue in 2022 |
$1.5 billion |
|
Estimated Value by 2027 |
$2.8 billion |
|
Growth Rate |
Poised to grow at a CAGR of 12.6% |
|
Largest Share Segments |
|
|
Market Report Segmentation |
Product, Technology, Application, End User, and Region |
|
Growth Drivers |
|
| Growth Opportunities |
|
|
Geographies covered |
North America, Europe, APAC, MEA, and Latin America |
In situ Hybridization Market Report Segmentation
By Product
- Consumables
- Kits & Reagents
- Probes
- Accessories
- Instruments
- Software
By Technology
- FISH
- DNA FISH
- RNA FISH
- PNA FISH
- CISH
By Application
- Cancer Diagnostics
- Cytology
- Infectious Disease Diagnostics
- Neuroscience
- Immunology
By End User
- Hospitals and Diagnostic Laboratories
- Academic and Research Institutes
- CROs
- Pharmaceutical and Biotechnology Companies
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- France
- UK
- Rest of Europe (RoE)
-
Asia Pacific (APAC)
- Japan
- India
- South Korea
- Rest of Asia Pacific (RoAPAC)
- Rest of the World (RoW)
Recent Developments:
- In 2022, RNAscope ISH Detection Kit manufactured by Bio-Techne received CE-IVD approval for the BOND-III platform (Leica Biosystems).
- In 2021, Applied Spectral Imaging (ASI) and KromaTiD, Inc. entered a strategic commercial partnership granting ASI worldwide rights to market KromaTiD’s proprietary Pinpoint FISH (PPF) probes and assay services.
- In 2020, Creative Bioarray introduced an advanced FISH probe to detect the 2019 Novel Coronavirus.
Frequently Asked Questions (FAQs):
What is the size of In Situ Hybridization Market?
The global In Situ Hybridization Market crossed $1.5 billion in 2022, and is poised to grow at a CAGR of 12.6% in the next five years to reach $2.8 billion.
Why is In Situ Hybridization Market Growing?
In situ hybridization is a powerful technique for detecting and analyzing gene expression at the cellular level. It has a wide range of applications in the fields of molecular biology, pathology, immunology, and developmental biology. The major factors driving the growth of the in situ hybridization market are the increasing research and development activities, growing adoption of in situ hybridization techniques in diagnostics, increasing prevalence of chronic diseases, and increasing public and private funding for research and development. Additionally, technological advances in in situ hybridization techniques and the increasing demand for personalized medicine are expected to further drive the growth of the in situ hybridization market.
Who all are the prominent players of In Situ Hybridization Market?
Some of the key players include Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (US) Danaher Corporation (US), Thermofisher Scientific (US), Abnova Corporation (Taiwan), BioGenex Laboratories (US), Bio-Techne Corporation (US), Biocare Medical, and Bio SB (US).
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 31)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.4 YEARS CONSIDERED
1.5 CURRENCY CONSIDERED
1.6 LIMITATIONS
1.7 STAKEHOLDERS
1.8 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 35)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 BREAKDOWN OF PRIMARIES: IN SITU HYBRIDIZATION MARKET
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 3 MARKET SIZE ESTIMATION (COMPANY REVENUE ANALYSIS-BASED ESTIMATION)
FIGURE 4 GLOBAL MARKET SIZE (USD MILLION)
FIGURE 5 GLOBAL MARKET: FINAL CAGR PROJECTIONS (2022−2027)
FIGURE 6 GLOBAL MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DEMAND-SIDE DRIVERS, OPPORTUNITIES, AND CHALLENGES
2.3 MARKET DATA ESTIMATION & TRIANGULATION
2.3.1 DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.4 INDUSTRY INSIGHTS
2.5 RESEARCH ASSUMPTIONS
3 EXECUTIVE SUMMARY (Page No. - 42)
FIGURE 8 IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
FIGURE 9 GLOBAL MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
FIGURE 10 FLUORESCENT IN-SITU HYBRIDIZATION MARKET SHARE, BY TYPE, 2021
FIGURE 11 GLOBAL MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 12 GLOBAL MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF GLOBAL MARKET
4 PREMIUM INSIGHTS (Page No. - 46)
4.1 GLOBAL MARKET OVERVIEW
FIGURE 14 GROWING FOCUS ON COMPANION DIAGNOSTICS AND RISING INCIDENCE OF CANCER & GENETIC DISORDERS TO DRIVE MARKET
4.2 NORTH AMERICA: MARKET
FIGURE 15 CONSUMABLES TO COMMAND LARGEST SHARE IN 2021
4.3 GLOBAL MARKET: BY REGION AND END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 16 HOSPITALS & DIAGNOSTIC LABORATORIES SEGMENT TO GROW AT HIGHEST CAGR IN NORTH AMERICA
5 MARKET OVERVIEW (Page No. - 48)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 17 IN SITU HYBRIDIZATION MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
TABLE 1 GLOBAL MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Rising incidence of genetic disorders and cancer
5.2.1.2 Growing awareness of companion diagnostics
5.2.2 OPPORTUNITIES
5.2.2.1 Emerging economies
5.2.3 CHALLENGES
5.2.3.1 Shortage of skilled professionals
5.3 PORTER’S FIVE FORCES ANALYSIS
TABLE 2 GLOBAL MARKET: PORTER’S FIVE FORCES ANALYSIS
5.3.1 THREAT OF NEW ENTRANTS
5.3.2 THREAT OF SUBSTITUTES
5.3.3 BARGAINING POWER OF BUYERS
5.3.4 BARGAINING POWER OF SUPPLIERS
5.3.5 INTENSITY OF COMPETITIVE RIVALRY
5.4 SUPPLY CHAIN ANALYSIS
FIGURE 18 GLOBAL MARKET: SUPPLY CHAIN
5.5 VALUE CHAIN ANALYSIS
FIGURE 19 VALUE CHAIN ANALYSIS OF THE GLOBAL MARKET
5.6 ECOSYSTEM ANALYSIS
FIGURE 20 GLOBAL MARKET: ECOSYSTEM ANALYSIS
5.7 KEY CONFERENCES & EVENTS (2020-2022)
5.7.1 IN SITU HYBRIDIZATION CONFERENCES (2022)
TABLE 3 IN SITU HYBRIDIZATION CONFERENCES (2022)
5.7.2 IN SITU HYBRIDIZATION CONFERENCES (2021)
5.7.3 IN SITU HYBRIDIZATION CONFERENCES (2020)
TABLE 4 IN SITU HYBRIDIZATION CONFERENCES (2020)
5.8 REGULATORY ANALYSIS (IN SITU HYBRIDIZATION)
5.8.1 FDA APPROVALS
5.8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 5 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 6 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.9 PRICING ANALYSIS
TABLE 9 PRICING ANALYSIS OF IN SITU PRODUCTS
5.9.1 GLOBAL MARKET: AVERAGE SELLING PRICE TREND FOR TREATMENT
6 IN SITU HYBRIDIZATION MARKET, BY PRODUCT (Page No. - 59)
6.1 INTRODUCTION
TABLE 10 GLOBAL MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
6.2 CONSUMABLES
TABLE 11 GLOBAL MARKET FOR CONSUMABLES, BY TYPE, 2020–2027 (USD MILLION)
TABLE 12 GLOBAL MARKET FOR CONSUMABLES, BY REGION, 2020–2027 (USD MILLION)
TABLE 13 NORTH AMERICA: MARKET FOR CONSUMABLES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 14 EUROPE: MARKET FOR CONSUMABLES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 15 ASIA PACIFIC: MARKET FOR CONSUMABLES, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.1 PROBES
6.2.1.1 Preference for direct localization of DNA/RNA sequences using probes
TABLE 16 GLOBAL MARKET FOR PROBES, BY REGION, 2020–2027 (USD MILLION)
TABLE 17 NORTH AMERICA: MARKET FOR PROBES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 18 EUROPE: MARKET FOR PROBES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 19 ASIA PACIFIC: MARKET FOR PROBES, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.2 KITS & REAGENTS
6.2.2.1 Growing focus on companion diagnostics to drive demand
TABLE 20 GLOBAL MARKET FOR KITS & REAGENTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 21 NORTH AMERICA: MARKET FOR KITS & REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 22 EUROPE: MARKET FOR KITS & REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 23 ASIA PACIFIC: MARKET FOR KITS & REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.3 ACCESSORIES
TABLE 24 IN SITU HYBRIDIZATION MARKET FOR ACCESSORIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 25 NORTH AMERICA: MARKET FOR ACCESSORIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 26 EUROPE: MARKET FOR ACCESSORIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 27 ASIA PACIFIC: MARKET FOR ACCESSORIES, BY COUNTRY, 2020–2027 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 RISING DEMAND FOR AUTOMATED SYSTEMS TO SUPPORT MARKET GROWTH
TABLE 28 GLOBAL MARKET FOR INSTRUMENTS, BY REGION, 2020–2027 (USD MILLION)
TABLE 29 NORTH AMERICA: MARKET FOR INSTRUMENTS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 30 EUROPE: MARKET FOR INSTRUMENTS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 31 ASIA PACIFIC: MARKET FOR INSTRUMENTS, BY COUNTRY, 2020–2027 (USD MILLION)
6.4 SOFTWARE
6.4.1 RISING NEED FOR HIGH-SPEED SAMPLE DATA ANALYSIS TO DRIVE MARKET
TABLE 32 GLOBAL MARKET FOR SOFTWARE, BY REGION, 2020–2027 (USD MILLION)
TABLE 33 NORTH AMERICA: MARKET FOR SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 34 EUROPE: MARKET FOR SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 35 ASIA PACIFIC: MARKET FOR SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION)
7 IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY (Page No. - 71)
7.1 INTRODUCTION
TABLE 36 GLOBAL MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
7.2 FLUORESCENT IN SITU HYBRIDIZATION
TABLE 37 FLUORESCENT IN-SITU HYBRIDIZATION MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 38 FLUORESCENT IN-SITU HYBRIDIZATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 39 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 40 EUROPE: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 41 ASIA PACIFIC: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.1 DNA FLUORESCENT IN SITU HYBRIDIZATION
7.2.1.1 Rising need to ensure stability of genetic material to drive market
TABLE 42 DNA FLUORESCENT IN-SITU HYBRIDIZATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 43 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 44 EUROPE: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 45 ASIA PACIFIC: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.2 RNA FLUORESCENT IN SITU HYBRIDIZATION
7.2.2.1 Increasing biomedical research activity to support market growth
TABLE 46 RNA FLUORESCENT IN-SITU HYBRIDIZATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 47 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 48 EUROPE: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 49 ASIA PACIFIC: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.3 PNA FLUORESCENT IN SITU HYBRIDIZATION
7.2.3.1 Utilization of PNA FISH for infectious disease control to drive market
TABLE 50 PNA FLUORESCENT IN-SITU HYBRIDIZATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 51 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 52 EUROPE: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 53 ASIA PACIFIC: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.3 CHROMOGENIC IN SITU HYBRIDIZATION
7.3.1 COST-EFFECTIVE ALTERNATIVE TO FISH TO SUPPORT MARKET GROWTH
TABLE 54 CHROMOGENIC IN-SITU HYBRIDIZATION MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 55 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 56 EUROPE: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 57 ASIA PACIFIC: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
8 IN SITU HYBRIDIZATION MARKET, BY APPLICATION (Page No. - 81)
8.1 INTRODUCTION
TABLE 58 GLOBAL MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
8.2 CANCER DIAGNOSTICS
8.2.1 INCREASING UTILIZATION OF FISH IN COMPANION DIAGNOSTICS TO DRIVE MARKET
TABLE 59 GLOBAL MARKET FOR CANCER DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION)
TABLE 60 NORTH AMERICA: MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 61 EUROPE: MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 62 ASIA PACIFIC: MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
8.3 CYTOLOGY
8.3.1 IDENTIFICATION OF CYTOGENETIC ALTERATIONS TO DRIVE DEMAND FOR FISH
TABLE 63 MARKET FOR CYTOLOGY, BY REGION, 2020–2027 (USD MILLION)
TABLE 64 NORTH AMERICA: MARKET FOR CYTOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 65 EUROPE: MARKET FOR CYTOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 66 ASIA PACIFIC: MARKET FOR CYTOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
8.4 INFECTIOUS DISEASE DIAGNOSTICS
8.4.1 RISING NEED FOR HIGH SENSITIVITY AND SPECIFICITY IN EARLY DISEASE DIAGNOSIS TO SUPPORT MARKET
TABLE 67 GLOBAL MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION)
TABLE 68 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 69 EUROPE: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 70 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
8.5 NEUROSCIENCE
8.5.1 RISING BURDEN OF NEUROLOGICAL DISORDERS TO DRIVE DEMAND FOR ISH
TABLE 71 GLOBAL MARKET FOR NEUROSCIENCE, BY REGION, 2020–2027 (USD MILLION)
TABLE 72 NORTH AMERICA: MARKET FOR NEUROSCIENCE, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 73 EUROPE: MARKET FOR NEUROSCIENCE, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 74 ASIA PACIFIC: MARKET FOR NEUROSCIENCE, BY COUNTRY, 2020–2027 (USD MILLION)
8.6 IMMUNOLOGY
8.6.1 RISING INCIDENCE OF AUTOIMMUNE DISEASES TO SUPPORT MARKET
TABLE 75 GLOBAL MARKET FOR IMMUNOLOGY, BY REGION, 2020–2027 (USD MILLION)
TABLE 76 NORTH AMERICA: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 77 EUROPE: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 78 ASIA PACIFIC: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
9 GLOBAL MARKET, BY END USER (Page No. - 92)
9.1 INTRODUCTION
TABLE 79 GLOBAL MARKET, BY END USER, 2020–2027 (USD MILLION)
9.2 HOSPITALS AND DIAGNOSTIC LABORATORIES
9.2.1 HOSPITAL-BASED LABS ARE ACCESSIBLE AND OFFER RAPID TEST RESULTS
TABLE 80 GLOBAL MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 81 NORTH AMERICA: MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 82 EUROPE: MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 83 ASIA PACIFIC: MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
9.3 ACADEMIC & RESEARCH INSTITUTES
9.3.1 INCREASING R&D ACTIVITIES FOR CHROMOSOMAL ABNORMALITIES TO SUPPORT MARKET GROWTH
TABLE 84 GLOBAL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
TABLE 85 NORTH AMERICA: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 86 EUROPE: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 87 ASIA PACIFIC: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.4.1 RISING DEMAND FOR PRECISION TREATMENTS TO DRIVE MARKET
TABLE 88 GLOBAL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 89 NORTH AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 90 EUROPE: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 91 ASIA PACIFIC: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
9.5 CONTRACT RESEARCH ORGANIZATIONS
9.5.1 INCREASING OUTSOURCING OF RESEARCH ACTIVITIES TO SUPPORT MARKET GROWTH
TABLE 92 GLOBAL MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 93 NORTH AMERICA: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 94 EUROPE: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 95 ASIA PACIFIC: MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
10 IN SITU HYBRIDIZATION MARKET, BY REGION (Page No. - 101)
10.1 INTRODUCTION
TABLE 96 GLOBAL MARKET, BY REGION, 2020–2027 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 21 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET SNAPSHOT
TABLE 97 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 98 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 99 NORTH AMERICA: FLUORESCENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 100 NORTH AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 101 NORTH AMERICA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 102 NORTH AMERICA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027(USD MILLION)
TABLE 103 NORTH AMERICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.2.1 US
10.2.1.1 Rising government funding for life science research to drive market
TABLE 104 US: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 105 US: FLUORESCENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 106 US: MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 107 US: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 108 US: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 109 US: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Increasing investments in genomics research to drive market
TABLE 110 CANADA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 111 CANADA: FLUORESCENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 112 CANADA: MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 113 CANADA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 114 CANADA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 115 CANADA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.3 EUROPE
TABLE 116 EUROPE: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 117 EUROPE: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 118 EUROPE: FLUORESCENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 119 EUROPE: MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 120 EUROPE: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 121 EUROPE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 122 EUROPE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Rising demand for technologically advanced diagnostic procedures to drive market
TABLE 123 GERMANY: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 124 GERMANY: FLUORESCENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 125 GERMANY: MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 126 GERMANY: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 127 GERMANY: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 128 GERMANY: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.3.2 FRANCE
10.3.2.1 Growing investments in proteomics and genomics to drive market
TABLE 129 FRANCE: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 130 FRANCE: FLUORESCENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 131 FRANCE: MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 132 FRANCE: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 133 FRANCE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 134 FRANCE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.3.3 UK
10.3.3.1 Growing focus on cancer research to drive market for ISH
TABLE 135 UK: IN-SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 136 UK: FLUORESCENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 137 UK: MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 138 UK: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 139 UK: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 140 UK: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.3.4 REST OF EUROPE (ROE)
TABLE 141 REST OF EUROPE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 142 REST OF EUROPE: FLUORESCENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 143 REST OF EUROPE: MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 144 REST OF EUROPE: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 145 REST OF EUROPE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 146 REST OF EUROPE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 22 ASIA PACIFIC: IN-SITU HYBRIDIZATION MARKET SNAPSHOT
TABLE 147 ASIA PACIFIC: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 148 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 149 ASIA PACIFIC: FLUORESCENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 150 ASIA PACIFIC: MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 151 ASIA PACIFIC: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 152 ASIA PACIFIC: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 153 ASIA PACIFIC: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.4.1 JAPAN
10.4.1.1 Rising focus on personalized diagnostics products to support market growth
TABLE 154 JAPAN: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 155 JAPAN: FLUORESCENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 156 JAPAN: MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 157 JAPAN: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 158 JAPAN: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 159 JAPAN: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.4.2 CHINA
10.4.2.1 Rising annual R&D investments to drive market demand for FISH and CISH-based kits
TABLE 160 CHINA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 161 CHINA: FLUORESCENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 162 CHINA: MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 163 CHINA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 164 CHINA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 165 CHINA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Collaborations between hospitals and diagnostics centers for laboratory services to drive market
TABLE 166 INDIA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 167 INDIA: FLUORESCENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 168 INDIA: MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 169 INDIA: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 170 INDIA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 171 INDIA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.4.4 REST OF ASIA PACIFIC
TABLE 172 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 173 REST OF ASIA PACIFIC: FLUORESCENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 174 REST OF ASIA PACIFIC: MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 175 REST OF ASIA PACIFIC: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 176 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 177 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
10.5 REST OF THE WORLD (ROW)
TABLE 178 REST OF THE WORLD: MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 179 REST OF THE WORLD: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 180 REST OF THE WORLD: FLUORESCENT MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 181 REST OF THE WORLD: MARKET, BY END USER, 2020–2027 (USD MILLION)
TABLE 182 REST OF THE WORLD: MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 183 REST OF THE WORLD: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 184 REST OF THE WORLD: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
11 COMPETITIVE LANDSCAPE (Page No. - 139)
11.1 INTRODUCTION
11.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT-TO-WIN ANALYSIS
FIGURE 23 IN SITU HYBRIDIZATION MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
11.3 MARKET SHARE ANALYSIS
FIGURE 24 GLOBSL MARKET: MARKET SHARE ANALYSIS FOR KEY PLAYERS (2021)
11.4 REVENUE SHARE ANALYSIS
FIGURE 25 REVENUE ANALYSIS FOR KEY COMPANIES (2019−2021)
11.5 COMPANY EVALUATION QUADRANT
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 26 GLOBAL MARKET: COMPANY EVALUATION MATRIX (2021)
11.6 COMPANY EVALUATION QUADRANT: STARTUPS/SMES
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
FIGURE 27 IN-SITU HYBRIDIZATION MARKET: COMPANY EVALUATION QUADRANT (2021)
11.6.5 COMPETITIVE BENCHMARKING
11.6.5.1 GLOBAL MARKET: Startups/SMEs
TABLE 185 LIST OF GLOBAL MARKET: STARTUPS/SMES
11.6.5.2 In situ hybridization market: Competitive benchmarking of key players [startups/SMEs)
TABLE 186 GLOBAL MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS [STARTUPS/SMES]
11.7 COMPETITIVE SCENARIO AND TRENDS
11.7.1 DEALS
TABLE 187 GLOBAL MARKET: DEALS
11.7.2 PRODUCT LAUNCHES
TABLE 188 GLOBAL MARKET: PRODUCT LAUNCHES
12 COMPANY PROFILES (Page No. - 151)
12.1 KEY COMPANIES
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
12.1.1 ABBOTT
TABLE 189 ABBOTT: BUSINESS OVERVIEW
FIGURE 28 ABBOTT: COMPANY SNAPSHOT
TABLE 190 ABBOTT: PRODUCTS OFFERED
12.1.2 F. HOFFMANN-LA ROCHE AG
TABLE 191 F. HOFFMANN-LA ROCHE LTD: BUSINESS OVERVIEW
FIGURE 29 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
TABLE 192 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
TABLE 193 F. HOFFMANN-LA ROCHE LTD: PRODUCT APPROVALS
12.1.3 THERMO FISHER SCIENTIFIC INC.
TABLE 194 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
TABLE 195 THERMO FISHER SCIENTIFIC: PRODUCTS OFFERED
12.1.4 DANAHER
TABLE 196 DANAHER: BUSINESS OVERVIEW
FIGURE 30 DANAHER: COMPANY SNAPSHOT
TABLE 197 DANAHER: PRODUCTS OFFERED
TABLE 198 PRODUCT APPROVALS
12.1.5 AGILENT TECHNOLOGIES, INC.
TABLE 199 AGILENT TECHNOLOGIES, INC: BUSINESS OVERVIEW
TABLE 200 AGILENT TECHNOLOGIES, INC: PRODUCTS OFFERED
12.1.6 BIOCARE MEDICAL, LLC
TABLE 201 BIOCARE MEDICAL, LLC: BUSINESS OVERVIEW
TABLE 202 BIOCARE MEDICAL, LLC: PRODUCTS OFFERED
12.1.7 BIO-TECHNE CORPORATION
TABLE 203 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW
TABLE 204 BIO-TECHNE: PRODUCT LAUNCHES
12.1.8 QIAGEN N.V.
TABLE 205 QIAGEN N.V.: BUSINESS OVERVIEW
TABLE 206 QIAGEN N.V.: PRODUCTS OFFERED
12.1.9 MERCK KGAA
TABLE 207 MERCK KGAA: BUSINESS OVERVIEW
TABLE 208 MERCK KGAA: PRODUCTS OFFERED
12.1.10 PERKINELMER
TABLE 209 PERKINELMER: BUSINESS OVERVIEW
TABLE 210 PERKINELMER: PRODUCTS OFFERED
12.1.11 ENZO BIOCHEM
TABLE 211 ENZO BIOCHEM: BUSINESS OVERVIEW
FIGURE 31 ENZO BIOCHEM: COMPANY SNAPSHOT
TABLE 212 ENZO BIOCHEM: PRODUCTS OFFERED
12.1.12 BIO-RAD LABORATORIES
TABLE 213 BIO-RAD LABORATORIES: BUSINESS OVERVIEW
TABLE 214 BIO-RAD LABORATORIES: PRODUCTS OFFERED
12.1.13 ABNOVA CORPORATION
TABLE 215 ABNOVA CORPORATION: BUSINESS OVERVIEW
TABLE 216 ABNOVA CORPORATION: PRODUCTS OFFERED
12.1.14 BIOGENEX LABORATORIES
TABLE 217 BIOGENEX LABORATORIES: BUSINESS OVERVIEW
TABLE 218 BIOGENEX LABORATORIES: PRODUCTS OFFERED
12.1.15 OPGEN
TABLE 219 OPGEN: BUSINESS OVERVIEW
TABLE 220 OPGEN INC: PRODUCTS OFFERED
12.1.16 BIO SB
TABLE 221 BIO SB: BUSINESS OVERVIEW
TABLE 222 BIO SB: PRODUCTS OFFERED
12.1.17 ABCAM
TABLE 223 ABCAM: BUSINESS OVERVIEW
TABLE 224 ABCAM: PRODUCTS OFFERED
12.1.18 ZYTOMED SYSTEMS GMBH
TABLE 225 ZYTOMED SYSTEMS GMBH: BUSINESS OVERVIEW
TABLE 226 ZYTOMED SYSTEMS: PRODUCTS OFFERED
12.1.19 NEOGENOMICS LABORATORIES
TABLE 227 NEOGENOMICS LABORATORIES: BUSINESS OVERVIEW
TABLE 228 NEOGENOMICS LABORATORIES: PRODUCTS OFFERED
12.1.20 BIOVIEW
TABLE 229 BIOVIEW: BUSINESS OVERVIEW
TABLE 230 BIOVIEW: PRODUCTS OFFERED
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
12.2 OTHER PLAYERS
12.2.1 GENEMED BIOTECHNOLOGIES
TABLE 231 GENEMED BIOTECHNOLOGIES: BUSINESS OVERVIEW
12.2.2 CREATIVE BIOARRAY
TABLE 232 CREATIVE BIOARRAY: BUSINESS OVERVIEW
12.2.3 BIOCAT GMBH
TABLE 233 BIOCAT GMBH: BUSINESS OVERVIEW
12.2.4 OXFORD GENE TECHNOLOGY
TABLE 234 OXFORD GENE TECHNOLOGY: BUSINESS OVERVIEW
12.2.5 ZYTOVISION
TABLE 235 ZYTOVISION: BUSINESS OVERVIEW
13 APPENDIX (Page No. - 195)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
This study involved four major activities in estimating the current size of the in situ hybridization market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the in situ hybridization market. The secondary sources used for this study include Some of the key secondary sources referred to for this study include publications from government sources World Health Organization (WHO), Organization for Economic Co-operation and Development (OECD), GLOBOCAN, World Bank, World Cancer Research Fund, Centers for Disease Control and Prevention (CDC), American Cancer Society (ACS), American Association for Clinical Chemistry, US Food and Drug Administration (FDA). These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the in situ hybridization market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and market have been identified through extensive secondary research
- The revenues generated from the in situ hybridization business of leading players have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Data Triangulation
After arriving at the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Report Objectives
- To define, describe, and forecast the in situ hybridization market based on product, technology, application, end user, and region
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, opportunities and trends)
- To strategically analyse micromarkets with respect to individual growth trends, future prospects, and contributions to the overall in situ hybridization market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, Asia Pacific, Rest of the World
- To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the in situ hybridization market.
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Company Information
- An additional five company profiles
Regional Analysis
- Breakdown of RoW into Latin America and Middle East & Africa
Growth opportunities and latent adjacency in In Situ Hybridization Market